Published in Hepatology on November 01, 1994
Animal models of portal hypertension. World J Gastroenterol (2006) 1.30
Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome. Gut (2001) 1.17
Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy. World J Hepatol (2016) 0.81
Gastric mucosal resistance to acute injury in experimental portal hypertension. Br J Pharmacol (2001) 0.77
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology (2001) 6.88
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet (1995) 6.06
Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med (1999) 5.89
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96
Randomised trial of endoscopic sphincterotomy with gallbladder left in situ versus open surgery for common bileduct calculi in high-risk patients. Lancet (1996) 3.81
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (1998) 3.62
Ramipril and the development of diabetes. JAMA (2001) 3.38
The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 3.11
Compensated cirrhosis: natural history and prognostic factors. Hepatology (1987) 3.01
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology (1990) 2.99
Gastric intramucosal acidosis in mechanically ventilated patients: role of mucosal blood flow. Crit Care Med (1998) 2.99
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology (1996) 2.96
Injection treatment of hemorrhage induced by endoscopic sphincterotomy. Endoscopy (1998) 2.87
Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol (2001) 2.73
Effects of somatostatin on renal function in cirrhosis. Gastroenterology (1992) 2.68
Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 2.57
Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology (1995) 2.47
Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut (2000) 2.30
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 2.30
Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology (1994) 2.27
Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology (2000) 2.22
Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol (2000) 2.22
Long-term outcome of patients with asystole induced by head-up tilt test. Eur Heart J (2002) 2.21
Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis (1999) 2.15
Ictal laughter associated with paroxysmal hypothalamopituitary dysfunction. Epilepsia (1997) 2.14
A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology (2001) 2.14
S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol (1999) 2.14
Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology (1998) 2.10
P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology (2002) 2.05
[Current status of clinical nutrition at the network of public hospitals from Castilla y León]. Nutr Hosp (2006) 2.02
Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology (1996) 2.00
Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology (1993) 1.97
Beta-blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology (1989) 1.97
Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia (2011) 1.94
Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol (1999) 1.92
Circulating levels of endothelin in cirrhosis. Gastroenterology (1993) 1.91
Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol (2001) 1.90
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J (2004) 1.90
Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol (2001) 1.89
Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet (1991) 1.88
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology (1998) 1.87
Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet (1989) 1.86
Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology (1997) 1.85
Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol (1986) 1.84
Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology (1998) 1.83
Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology (1993) 1.79
Gastric mucosal vascular ectasias causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I. Gastroenterology (1987) 1.77
Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology (1988) 1.76
Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol (1998) 1.76
Short-term outcome analysis of a randomized study comparing laparoscopic vs open colectomy for colon cancer. Surg Endosc (1995) 1.74
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology (1988) 1.74
A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain (2009) 1.69
Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology (1996) 1.68
Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology (1990) 1.67
Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology (1983) 1.67
Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology (2000) 1.67
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology (1993) 1.67
Fulminant hepatic failure. Lancet (1997) 1.66
In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology (2001) 1.66
Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology (1999) 1.64
Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology (1996) 1.64
Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology (2001) 1.62
Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology (1999) 1.62
Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients. Aliment Pharmacol Ther (2009) 1.62
Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology (1998) 1.60
The lung in patients with cirrhosis. J Hepatol (1990) 1.59
Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis (1976) 1.59
Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes (2000) 1.58
Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet (1993) 1.57
Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology (1992) 1.57